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Abstract 
Purpose: The PARP inhibitor, Olaparib, is approved for women with BRCA-
mutated ovarian cancer. Therefore there is an urgent need to test patients 
and obtain results in time to influence treatment. Models of BRCA testing such 
as the Mainstreaming Oncogenetic pathway, involving oncology healthcare 
professionals are being utilised. Here we report on the establishment of the 
extended role of the Clinical Nurse Specialist in consenting women for BRCA 
testing in routine gynaecology-oncology clinics using the Mainstreaming 
Model. 
Methods: Nurses undertook generic consent training and specific counselling 
training for BRCA testing in the form of a series of online videos, written 
materials and checklists prior to obtaining approval to consent patients for 
germline BRCA1 and BRCA2 mutations. 
Results: Between July 2013 and December 2015, 108 women with ovarian 
cancer were counselled and consented by nurses in the medical oncology 
clinics at a single centre (The Royal Marsden, UK). This represented 36% of 
all ovarian cancer patients offered BRCA testing in the oncology clinics. 
Feedback from patients and nurses was encouraging with no significant 
issues raised in the counselling and consenting process. 
Conclusion: The mainstreaming model allows for greater access to BRCA 
testing for ovarian cancer patients, many of whom may benefit from 
personalised therapy (PARP inhibitors). This is the first report of oncology 
nurses in the BRCA testing pathway. We have shown that specialist oncology 
nurses trained in BRCA testing have an important role within a 
multidisciplinary team counselling and consenting patients to undergo BRCA 
testing. 
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Introduction 
The significance of germline BRCA testing in ovarian cancer to identify 
hereditary risks and clinical consequences has come to the forefront over the 
last few years.  Moreover, the European Medicines Agency (EMA) and FDA 
approval of Olaparib (Lynparza) at the end of 2014, the first targeted therapy 
(PARP inhibitor) for BRCA mutation-associated ovarian cancer 
(http://www.ema.europa.eu/ema/  http://www.fda.gov/) means that there is an 
urgent need to deliver more widespread BRCA testing in routine clinical 
practice.   In England, from April 2016, patients with BRCA- mutated, 
platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer who 
have had 3 or more courses of platinum-based chemotherapy can access 
Olaparib through the National Health Service (NHS) 
(www.nice.org.uk/guideance/ta381 accessed May 2016)  
 
PARP inhibitors exploit the concept of “synthetic lethality”- targeting one of the 
genes in a synthetic lethal pair, where the other is defective (eg. BRCA 
mutation), selectively kills tumour cells while sparing normal cells (thereby 
limiting toxicity). The pivotal clinical trial that led to the licensing of the first 
PARP inhibitor, olaparib, is a double-blind, placebo- controlled randomized 
phase II study in which patients with platinum-sensitive, recurrent, high-grade 
serous ovarian cancer (who had achieved a response following their most 
recent platinum-based regimen) were randomised to either olaparib or 
placebo maintenance therapy. In a subgroup analysis, patients with a BRCA 
mutation were shown to have a significant benefit from olaparib compared 
with placebo with an 82% improvement in progression-free survival. (median 
PFS BRCA mutation group 11.2 vs 4.3 months; HR=ratio, 0.18, 95% CI, 0.10-
0.31; P<.0001).  
 
Ovarian cancer is the fourth most common cause of cancer death for women 
in the UK- there were are over 7000 new cases and more than 4000 deaths in 
2012/2013 (Cancer Research UK, 2013).  It is now recognised that the 
incidence of BRCA germline mutations in epithelial ovarian cancer (EOC) is 
likely to be higher than previously believed (Moschetta et al 2016). In a study 
of 1001 patients, the overall incidence of germline BRCA mutations in non-
mucinous EOC was 14.1%: the rate was even higher (17.1%) in patients with 
high grade serous adenocarcinoma, which is the most common histological 
subtype It is particularly noteworthy that 44% of women with germ-line BRCA 
mutations did not report a relevant family history of cancer (Alsop et al 2012). 
This means that up until recently, according to most international testing 
criteria; these women would not have been eligible for BRCA testing.  
 
Knowledge of the germline BRCA mutation status not only provides important 
clinical information for the management of patients (prognostic information, 
predicting response to chemotherapy, access to PARP inhibitors, screening 
for breast cancer) but also has consequences for family members (cancer 
screening, consideration of prophylactic measures) who have a 50% risk of 
inheriting a BRCA mutation (Banerjee et al 2010). 
 
Up until recently, clinical practice for the majority of cancer patients worldwide 
was to be offered BRCA testing through referrals to the genetics team 
(Moschetta et al, 2016) However, there is a valid concern from genetics and 
oncology experts worldwide that the volume of patients who may benefit from 
BRCA testing may overwhelm current genetic services (Rahman, 2014 and 
Slade et al 2014). The time from the genetics referral  to results has been in 
excess of 6 months (George BJC 2015). Therefore, innovative approaches to 
BRCA testing on a wider scale need to be considered, as the demand for 
BRCA testing is increasing amongst patients, family members and cancer 
clinicians.  The Royal Marsden team piloted a new ‘oncogenetic pathway’ of 
BRCA testing in routine ovarian cancer clinical practice as part of the 
Mainstreaming Cancer Genetics Programme (MCG) 
(http://mcgprogramme.com) which aims to make genetic testing part of routine 
cancer patient care. In the pilot study, between July 2013 and January 2014, 
119 women with serous or endometrioid ovarian cancer under the age of 65 
were tested for BRCA mutations using the BRCA testing protocol in the 
medical oncology clinics (figure 1). The BRCA mutation rate within this group 
of women was 16.8%.  Strikingly, more than 50% of women tested had no 
family or personal history of breast or ovarian cancer and therefore under 
previous testing guidelines, would not have been eligible for BRCA testing 
(George et al 2014). 
 
 As an integral part of the oncology team, Clinical Nurse Specialist (CNS) are 
often the keyworker for patients throughout the cancer pathway (Cook et al 
2015). The scope of practice of many advanced nurses is expanding (Gray, 
2016) with many carrying out the necessary training and competencies to 
perform procedures such as ascetic drains, chemotherapy consent and HIV 
testing (Kwong and Gabler, 2015) in order to enhance the patient 
management pathway. Within oncology, many are now also consenting for 
trial screening, including testing for somatic and germline mutations to assess 
suitability for targeted treatments.  The process of informed consent mandates 
for all areas, and focuses on giving patients sufficient information about the 
investigation or intervention to be able to make an informed decision about 
whether or not to proceed.    
 
As new initiatives are developed, it is often appropriate for advanced nurses 
to become involved with service development to help meet patient needs, and 
address patient demands.  In view of the fact that nurses already are active in 
consenting patients for other investigations having had appropriate consent 
training, the addition of BRCA consent and associated counselling to the 
nurse portfolios was an obvious extension. The CNS’s were therefore asked 
to be key members of the Gynaecology Oncology team to help identify and 
consent women for BRCA gene mutations.  Herein, we report for the first time, 
the experience of CNS’s delivering counselling and consent for germline 
BRCA testing in cancer patients.  
 
Methods 
This is a descriptive report of the nursing experience of BRCA testing. This 
report includes outcomes of questionnaires that were distributed to 6 
Gynaecology Oncology CNS’s  who had completed the BRCA consent 
training to establish the nursing consensus of this advanced role within 
today’s practice. In addition, the patient experience of BRCA testing consent 
from nurses was obtained. 
 A service evaluation approved by the Royal Marsden Research and 
Development Committee, involving patient and healthcare professionals 
completing an online questionnaire was carried out for the first 119 patients 
undergoing BRCA testing using the mainstreaming model (George et al 
2014).  
 
Oncology healthcare professionals (consultants, trainees and nurses) were 
offered to undergo training delivered by the cancer genetics team on germline 
BRCA testing. CNS’s who had completed the hospital general consent 
training were offered the opportunity to take on this new role, with appropriate 
provision of training and support from the Oncology and Genetic teams. 
Training and certification of competency were mandatory prior to individuals 
approaching BRCA testing with patients. In addition, nurses were required to 
have completed general consent training. The learning resources pack for 
BRCA training consisted of a series of online videos and written material 
delivered by the genetics team. The material covered the protocol to identify 
patients; information regarding the relevance of BRCA testing; significance for 
patients with a normal BRCA result and those with a mutation identified; 
significance of a BRCA variant requiring evaluation, the implications for family 
members if a positive result was identified and frequently asked questions. 
Following completion of the training package, nurses completed a checklist 
and self-certification of competency to consent patients for BRCA testing.  All 
materials are available from http://www.mcgprogramme.com. Nurses were 
also given the opportunity to have face-to-face training and received 
supervision from the trained oncologists until confident. The testing protocol is 
shown in Figure 1. 
  
If a patient was identified as eligible for BRCA testing, then within the 
oncology clinics they were provided with written information on BRCA testing. 
Patients were often known by the CNS as they acted as their Key Worker. A 
discussion between the nurse and the patient would take place and the 
consent form would be discussed.  Patients were able to ask questions at any 
stage in the process and if the patient or nurse felt it necessary, patients could 
be referred to the genetics team directly at any point in the testing pathway. 
Following signing of the consent form by the patient and nurse, a BRCA test 
request form was completed by the nurse and given to the patient so they 
could proceed with the blood test. 
 
When patient results became available from the genetics team, within 8 
weeks they were entered on the electronic patient record system and sent to 
the consultant of the patient.  Nurses were able to deliver BRCA results where 
no mutation was identified directly to the patient in the oncology clinic.  
Following a year of this protocol, based on feedback from team members and 
patients, results in the form of a letter were sent directly to the patient   If a 
BRCA mutation was identified, in addition to oncologists explaining the 
relevance for oncological management, patients were automatically sent an 
appointment with the Genetics team for further discussion of hereditary 
implications, risk and screening for other cancers. There was the opportunity 
for Information to be provided by the Genetics team to family members of 
patients identified to carry a germline BRCA mutation and subsequent BRCA 
testing  
 
 
Results  
Evaluation of the BRCA testing model: nursing perspective 
 
Within the Gynaecology Unit, of the 25 healthcare professionals that 
underwent BRCA testing training, 4 (16%) were nurses. Analysis of the BRCA 
consents and request forms indicated that the highest recruiter of patients for 
BRCA testing was a CNS.  Of these 300 patients, 108 were counselled and 
consented by the CNS team, and 192 by doctors.  There was no difference in 
reported patient satisfaction between those consented by a nurse, or a doctor 
in the first 119 patients offered the questionnaire (George et al, 2014). 75 of 
the 108 patients consented by nurses completed the questionnaire.  A patient 
survey distributed to the pilot group of patients demonstrated that no patients 
refused testing, or requested a Genetics appointment prior to testing.  All 
healthcare professionals including nurses felt confident in consenting and 
giving results to patients, while none reported they were asked questions they 
were unable to answer after undergoing training. 
 
To further establish the views of the gynaecology nurses a questionnaire 
(figure 2) was sent to 6 nurses. 5/6 completed the questionnaire.  It included 7 
specific questions related to the extended role of consenting for BRCA testing.  
This included a question specific to nurses who had completed training and 
consented a patient and one question specific to nurses who had completed 
training but were yet to complete the consent process.  All CNS’s had 
completed BRCA specific consent training.  Responses to the questions 
indicated that all nurses found the BRCA training videos helpful and a good 
method of learning.  All nurses felt that BRCA testing was part of their role.  
All nurses commented on the importance of patients being offered BRCA 
testing. One nurse commented on the concerns she had about the BRCA 
testing being carried out in busy oncology clinics and discussed the 
anticipation of added time pressures; however those nurses who had 
performed the majority of the BRCA consents reported no significantly added 
time in consultations and no added pressures to the clinic.  All nurses involved 
felt well supported to undertake the BRCA consent and were reassured about 
the option of genetic follow up if required.  An example of a comment is ‘I felt 
reassurance as I knew if the patients had questions I was unable to answer I 
could refer them to the genetics team.’  One nurse felt that a barrier to the 
consenting process may be lack of time and this was the same nurse who 
raised concerns about already busy oncology clinics.  General comments on 
the BRCA consenting process emphasise the importance of CNS’s being well 
placed with in the oncology clinics to offer the testing as the patient 
advocates. Nurses were also very aware that discussing BRCA at initial 
consultations may not be the optimum time for patients as often there can be 
an overload of information. However nurses did feel it was their role as the 
patient advocate to re-visit this at a different appointment highlighting that 
nurses felt that this should be part of their responsibility in an advanced role 
   
 
 
 Discussion 
 
The implementation of BRCA testing within the medical oncology clinics is 
practice-changing. The revised eligibility criterion allows all patients with non-
mucinous epithelial ovarian cancer of any age to be offered BRCA testing. 
Based on the success of the pilot MCG study, this model is the current 
standard practice at the Royal Marsden. Knowledge of the BRCA mutation 
status has already helped guide patient management and following the recent 
licence of Olaparib, will be crucial for patients to access PARP inhibitors.  
 
When the pilot began the criteria were such that that some ovarian cancer 
patients were not eligible for testing.  Due to the demand and the success of 
the pilot BRCA gene testing, the current practice at the Royal Marsden is for 
the test to be offered to ovarian cancer patients of any age and with all non-
mucinous tumours. This is in line with NICE recommendations which includes 
germline BRCA testing of patients with ovarian cancer that have a combined 
BRCA1 and BRCA2 mutation carrier probability of 10% or more 
(https://www.nice.org.uk/guidance/cg164/chapter/1-recommendations). This 
has a significant impact on the patient and also their family members.  For 
patients who were found to have a BRCA mutation, treatment options 
potentially changed as they could have access to clinical trials involving PARP 
inhibitors.  With the continued development of PARP inhibitors and the recent 
olaparib licence, this additional information is paramount for ovarian cancer 
patients.  For women with a germline BRCA mutation, this also allowed family 
members to be tested. This has implications for prevention and screening 
which would be discussed in the genetics clinics. 
 
The CNS’s are ideally suited to be able to deliver information in BRCA testing 
and consenting.  In many cases, patients and their CNS already have an 
established rapport; ensuring patients are comfortable with the discussions, 
and feel able to ask questions that they may not otherwise do. These are also 
the reasons why the CNS team felt it was a natural expansion to their role and 
was well placed in the medical oncology clinics It is important to note that the 
nurses had the option of referring the patient to the Genetics department at 
any time, if they felt that the patient had questions that they could not address; 
although in practice, this has not occurred, Having such backup is vital.  
Nurses also have the advantage of continuity of care with patients, often more 
so than the frequently changing junior medical team.  
 
As genetic testing becomes a routine part of patient care, it will be important 
that all members of the team, including the CNS’s, have a good 
understanding of the implications of testing for both patients and their family 
members. It is important to point out that CNS’s are not discussing BRCA 
mutations with unaffected family members. Oncology nurses are important 
advocates to identify patients understanding and concerns during the BRCA 
testing process. Based on the Royal Marsden Experience so far, it is evident 
that the delivery of BRCA testing in oncology clinics by healthcare 
professionals including CNS’s is feasible and welcomed by patients, oncology 
and genetics teams.  It is critical that nurses are given adequate training and 
support for this combined oncology-genetics model to be successfully taken 
up by other cancer centres and benefit the overall quality of cancer care for 
patients.  
 
Patients are offered BRCA testing at any point in the care pathway. It was 
identified that this meant that patients under 6 month or annual follow-up may 
not receive the BRCA test result till their next routine clinic visit in 6 months to 
a year. Subsequent to the pilot phase, this issue has been addressed; the 
genetics team automatically send the BRCA result and information on the 
relevance of the result as soon as available thereby ensuring that patients 
receive results within 4 weeks, and are offered a genetics appointment if a 
BRCA mutation is identified. The revised pathway is more streamline for 
patients and means that patients get there results in a more timely fashion 
(currently 2-4 weeks at the Royal Marsden), with the aim to reduce any 
anxiety caused by waiting for results. An appointment with the genetics team 
is offered within 2-3 weeks of the patient receiving the result.  From a nursing 
perspective this is advantageous as it means that patients have time to think 
of any questions that they may have for the team or contact their CNS if they 
are unsure or concerned.  
 
Conclusion and recommendations for future practice 
 
Evaluation of this pathway showed that ovarian cancer patients were happy to 
receive BRCA testing in oncology appointments.  There were no concerns 
raised about receiving information or consent taking from nurses and in many 
cases the existing rapport between the CNS and the patients helped to 
facilitate discussion about BRCA and the consenting process. 
 
Individual trusts may have their own guidelines with relation to general 
consent, for CNS’S to add BRCA testing to their role general consent training 
would need to be undertaken in addition to specific BRCA consenting and 
training.  However as genetic testing becomes integrated into routine cancer 
care in ovarian cancer and other malignancies (eg. breast, pancreatic cancer) 
this will become an increasingly important aspect of scope of practice and 
patient care. 
 
Moving forward in practice it will be essential to gain further insight into the 
patient perceptions of BRCA testing and the experience of adding this 
additional testing to their cancer pathway. 
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